基因合成市场机会、成长驱动因素、产业趋势分析及预测（2025-2034年）

2024 年全球基因合成市场价值为 9.519 亿美元，预计到 2034 年将以 16.9% 的复合年增长率成长至 46 亿美元。

合成生物学的兴起、DNA合成技术的不断进步以及全球基因组学研究投资的不断增长推动了市场扩张。个人化医疗和生物标记开发的日益普及也增加了对高精度基因建构工具的需求。基因合成产业透过提供客製化基因合成​​、DNA文库建构和高级克隆服务，为製药公司、生物技术公司、学术研究中心和医疗技术开发商提供至关重要的解决方案。这些解决方案提高了基因工程工作流程、药物发现研究和分子诊断的效率。自动化合成平台和先进的纠错技术提高了准确性，同时降低了成本和周转时间，使基因合成得以广泛应用。政府和私人对大规模基因组学计画的投入不断增加，支持了基因合成在疾病建模、农业和工业生物技术领域的应用。合成基因在抗体工程、疫苗开发和治疗设计中的日益广泛的应用，持续推动着该行业向前发展。后疫情时代进一步凸显了快速合成基因生产对于加速治疗创新的重要性。

固相合成技术在2024年占据了58.6%的市场份额，这主要得益于其可扩展性、高精度以及适用于产生用于科研和商业用途的长DNA序列。其逐步添加核苷酸的方法提高了可靠性和纯化效率，使其成为一种首选的合成技术。

2024年，抗体DNA合成领域占了46.4%的市场份额，预计在预测期内将达到22亿美元。成长的主要驱动力是单株抗体疗法需求的不断增长，这些疗法广泛应用于癌症治疗、免疫系统疾病、传染病以及各种罕见疾病。这种需求的激增也增加了对客製化抗体基因的需求，以加速治疗药物的研发进程。

预计到2024年，北美基因合成市场将占据40.3%的份额。该地区的领先地位得益于大型生物技术和製药公司、强大的研究生态系统以及在基因组学和合成生物学领域的大量投资。完善的监管体系和先进的临床研究能力也持续推动基因合成技术的应用。

全球基因合成市场的主要参与者包括Azenta, Inc. (GENEWIZ)、BIOMATIK、Bio Basic Inc.、BIONEER CORPORATION、Gene Universal Inc.、Eurofins Scientific SE、Integrated DNA Technologies, Inc.、GenScript、Macrogen, Inc.、ProMcium Biotechnologies, Inc.、OGenemo Technologiesp. Inc.和Twist Bioscience Corporation。这些公司正透过扩大自动化合成平台规模、提升纠错能力以及拓展客製化基因设计服务来巩固其竞争优势。许多公司正与製药和生物技术公司建立策略合作伙伴关係，将合成技术直接整合到药物发现和抗体工程工作流程中。对高通量系统和云端序列设计工具的投资，能够加快专案週转速度并提升产能。

目录

第一章：方法论与范围

第二章：执行概要

第三章：行业洞察

• 产业生态系分析
  • 供应商格局
  • 每个阶段的价值增加
  • 影响价值链的因素
• 产业影响因素
  • 成长驱动因素
    • DNA合成技术的快速发展
    • 对基因合成专案和合成生物学研发的投资不断增长
    • 遗传性疾病和慢性病盛行率增加
    • 基因疗法的日益普及
  • 产业陷阱与挑战
    • 缺乏熟练的专业人员
    • 复杂的基因合成技术和高额的製程成本
  • 市场机会
    • 基于 CRISPR 的基因编辑应用程式扩展
    • 基于RNA的疫苗和疗法的开发
• 成长潜力分析
• 监管环境
  • 北美洲
  • 欧洲
  • 亚太地区
• 技术格局
  • 当前技术趋势
  • 新兴科技及其影响
• 未来市场趋势
• 定价分析
• 投资和融资环境
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 主要市场参与者的竞争分析
• 关键进展
  • 併购
  • 合作伙伴关係与合作
  • 新服务上线
  • 扩张计划

第五章：市场估计与预测：依方法划分，2021-2034年

• 主要趋势
• 固相合成
• 基于PCR的酶合成
• 基于晶片的合成

第六章：市场估计与预测：依服务业划分，2021-2034年

• 主要趋势
• 抗体DNA合成
• 病毒DNA合成
• 其他服务

第七章：市场估计与预测：依应用领域划分，2021-2034年

• 主要趋势
• 基因和细胞疗法开发
• 疾病诊断
• 疫苗研发
• 其他应用

第八章：市场估算与预测：依复杂程度划分，2021-2034年

• 主要趋势
• 标准基因合成
• 复杂基因合成

第九章：市场估算与预测：依最终用途划分，2021-2034年

• 主要趋势
• 生物製药公司
• 学术和研究机构
• 合约研究机构

第十章：市场估计与预测：依地区划分，2021-2034年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十一章：公司简介

• Azenta, Inc. (GENEWIZ)
• Bio Basic Inc.
• BIOMATIK
• BIONEER CORPORATION
• Eurofins Scientific SE
• Gene Universal Inc.
• GenScript
• Integrated DNA Technologies, Inc.
• Macrogen, Inc.
• OriGene Technologies, Inc.
• ProMab Biotechnologies, Inc.
• ProteoGenix
• Synbio Technologies
• Thermo Fisher Scientific Inc.
• Twist Bioscience Corporation

The Global Gene Synthesis Market was valued at USD 951.9 million in 2024 and is estimated to grow at a CAGR of 16.9% to reach USD 4.6 billion by 2034.

Market expansion is propelled by the rise of synthetic biology, continual progress in DNA synthesis technologies, and growing investments in genomics research worldwide. The expanding use of personalized medicine and biomarker development is also increasing the demand for high-precision gene construction tools. The gene synthesis industry provides essential solutions for pharmaceutical companies, biotechnology firms, academic research centers, and healthcare technology developers by offering custom gene synthesis, DNA library creation, and advanced cloning services. These solutions improve the efficiency of genetic engineering workflows, drug discovery studies, and molecular diagnostics. Automated synthesis platforms and sophisticated error-correction technologies have enhanced accuracy while reducing cost and turnaround time, making gene synthesis widely accessible. Increased government and private funding for large-scale genomics initiatives supports applications in disease modeling, agriculture, and industrial biotechnology. Growing utilization of synthetic genes in antibody engineering, vaccine development, and therapeutic design continues to push the industry forward. The post-pandemic landscape has further reinforced the importance of rapid synthetic gene production for accelerated therapeutic innovation.

The solid-phase synthesis segment held 58.6% share in 2024, driven by its scalability, high precision, and suitability for generating long DNA sequences for both research and commercial use. Its stepwise nucleotide addition method enhances reliability and purification efficiency, making it a preferred synthesis technique.

The antibody DNA synthesis segment accounted for a 46.4% share in 2024 and is projected to reach USD 2.2 billion during the forecast period. Growth is driven by rising demand for monoclonal antibody therapies used across cancer treatment, immune system disorders, infectious diseases, and various rare conditions. This surge has increased the need for custom-designed antibody genes to accelerate therapeutic development pipelines.

North America Gene Synthesis Market held a 40.3% share in 2024. The region's leadership is supported by major biotechnology and pharmaceutical companies, strong research ecosystems, and significant investment in genomics and synthetic biology. Supportive regulatory structures and advanced clinical research capabilities continue to elevate the adoption of gene synthesis technologies.

Prominent companies participating in the Global Gene Synthesis Market include Azenta, Inc. (GENEWIZ), BIOMATIK, Bio Basic Inc., BIONEER CORPORATION, Gene Universal Inc., Eurofins Scientific SE, Integrated DNA Technologies, Inc., GenScript, Macrogen, Inc., ProMab Biotechnologies, Inc., OriGene Technologies, Inc., ProteoGenix, Synbio Technologies, Thermo Fisher Scientific Inc., and Twist Bioscience Corporation. Companies in the Gene Synthesis Market are strengthening their competitive position by scaling up automated synthesis platforms, improving error-correction capabilities, and expanding their custom gene design services. Many firms are forming strategic partnerships with pharmaceutical and biotechnology companies to integrate synthesis technologies directly into drug discovery and antibody engineering workflows. Investments in high-throughput systems and cloud-based sequence design tools are enabling faster project turnaround and greater volume capacity.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Method trends
  • 2.2.3 Services trends
  • 2.2.4 Application trends
  • 2.2.5 Complexity trends
  • 2.2.6 End Use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factors affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rapid advancements in DNA synthesis technology
    • 3.2.1.2 Growing investments in gene synthesis projects and synthetic biology R&D
    • 3.2.1.3 Increased prevalence of genetic disorders and chronic disease
    • 3.2.1.4 Rising adoption of gene therapy
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of skilled professionals
    • 3.2.2.2 Complex gene synthesis techniques and high process cost
  • 3.2.3 Market opportunities
    • 3.2.3.1 Expansion of CRISPR-based gene editing applications
    • 3.2.3.2 RNA-based vaccines and therapeutics development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies and their impacts
• 3.6 Future market trends
• 3.7 Pricing analysis
• 3.8 Investment and funding landscape
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Competitive analysis of major market players
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New service launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Method, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Solid-phase synthesis
• 5.3 PCR-based enzyme synthesis
• 5.4 Chip-based synthesis

Chapter 6 Market Estimates and Forecast, By Services, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Antibody DNA synthesis
• 6.3 Viral DNA synthesis
• 6.4 Other services

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Gene and cell therapy development
• 7.3 Disease diagnosis
• 7.4 Vaccine development
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Complexity, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Standard gene synthesis
• 8.3 Complex gene synthesis

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Biopharmaceutical companies
• 9.3 Academic and research institutes
• 9.4 Contract research organizations

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Azenta, Inc. (GENEWIZ)
• 11.2 Bio Basic Inc.
• 11.3 BIOMATIK
• 11.4 BIONEER CORPORATION
• 11.5 Eurofins Scientific SE
• 11.6 Gene Universal Inc.
• 11.7 GenScript
• 11.8 Integrated DNA Technologies, Inc.
• 11.9 Macrogen, Inc.
• 11.10 OriGene Technologies, Inc.
• 11.11 ProMab Biotechnologies, Inc.
• 11.12 ProteoGenix
• 11.13 Synbio Technologies
• 11.14 Thermo Fisher Scientific Inc.
• 11.15 Twist Bioscience Corporation